The Digital Colonialism of Medical AI: How Western Corporations Endanger Global Health

The Troubling Case of Johnson & Johnson’s TruDi System

The recent revelations about Johnson & Johnson’s AI-powered TruDi Navigation System represent a catastrophic failure of medical ethics and regulatory oversight. According to comprehensive reporting, this medical device designed to treat chronic sinusitis has been linked to at least 100 malfunctions and injuries since its AI integration in 2021. The horrifying incidents include cerebrospinal fluid leaks, skull punctures, and strokes resulting from injuries to major arteries during surgical procedures. By November 2025, at least ten people had been reported injured, primarily due to incorrect information provided by the AI system during surgeries.

Two stroke victims have filed lawsuits in Texas claiming that the AI in the TruDi system caused their injuries. Erin Ralph underwent a procedure using the TruDi system in June 2022, during which the device allegedly misdirected the surgeon, resulting in injury to her carotid artery and causing a blood clot. After the surgery, Ralph suffered a stroke and required extensive recovery care, including a portion of her skull being removed to alleviate brain swelling. Similarly, in May 2023, Donna Fernihough suffered a stroke during a sinuplasty operation when her carotid artery was damaged, allegedly due to the TruDi system.

The Broader Context of AI in Healthcare

This case emerges against the backdrop of rapid AI integration in medical devices across the Western healthcare industry. The FDA now authorizes over 1,357 AI-enhanced medical devices—double the amount authorized by the end of 2022. Research from Johns Hopkins, Georgetown, and Yale found that 60 FDA-authorized medical devices using AI were involved in 182 recalls, with 43% of these recalls occurring within a year of approval—significantly higher than the typical recall rate for devices approved under similar FDA standards.

The rapid introduction of AI medical devices has challenged the FDA, which struggles to manage the influx while dealing with staffing losses. The Trump administration’s cost-cutting measures resulted in around 15 AI specialists being laid off or leaving the FDA’s Division of Imaging, Diagnostics, and Software Reliability. The Digital Health Center of Excellence, which focused on AI policy, lost about a third of its staff. Since these staffing cuts, some device reviewers have seen their workloads nearly double, increasing the likelihood of oversights.

Corporate Responsibility and Ethical Failures

Johnson & Johnson referred inquiries to Integra LifeSciences, which acquired Acclarent (the manufacturer of TruDi). Integra stated that the reports only showed that a TruDi system was used during surgeries where problems occurred and contended that there is no evidence linking the AI system to injuries. However, internal reports from 2021 revealed a push by Acclarent’s then-president, Jeff Hopkins, to incorporate AI into TruDi for marketing purposes. The lawsuit alleges that Acclarent rushed to market the technology without resolving safety issues, aiming for only 80% accuracy—a shockingly low threshold for medical devices that handle human lives.

Dr. Dean, who consulted for Acclarent since 2014, received over $550,000 in fees, including at least $135,000 related to the TruDi system. After Integra acquired Acclarent, they indicated that Dean was no longer a consultant and that post-acquisition payments were for meals—a questionable explanation that raises ethical concerns about the financial relationships between medical professionals and device manufacturers.

The Imperialistic Dimensions of Medical Technology

This case exemplifies the dangerous convergence of corporate greed, technological arrogance, and regulatory capture that characterizes Western approaches to global health. The rush to implement AI in medical devices without proper testing or oversight reflects a neo-colonial mindset that treats patients—particularly in the Global South—as expendable subjects for technological experimentation. Unlike drugs, medical devices do not always require clinical trials before approval, and many AI-enabled devices can enter the market by referencing existing non-AI devices. This regulatory gap creates a perverse incentive for corporations to prioritize speed to market over patient safety.

The fact that Western regulatory agencies are struggling to keep pace with AI advancements while simultaneously facing budget cuts reveals a fundamental hypocrisy. These same Western nations impose stringent regulations on products from the Global South while allowing their own corporations to deploy inadequately tested technologies that endanger lives worldwide. This double standard represents a form of technological imperialism that must be vehemently opposed.

The Human Cost of Technological Arrogance

The stories of Erin Ralph and Donna Fernihough are not isolated incidents—they represent the human cost of a system that values profit over people. When corporations aim for 80% accuracy in medical devices, they are effectively accepting that 20% of patients will be harmed by their technology. This calculation is not just unethical—it is fundamentally anti-human and reflects the worst aspects of Western capitalist approaches to healthcare.

The FDA’s admission that reports of device malfunctions are limited and often lack details, and that these reports alone cannot assign blame, creates a accountability vacuum that corporations exploit. When regulatory agencies are understaffed and overwhelmed, and when corporations can hide behind complex corporate structures and legal technicalities, patients are left without recourse or justice.

A Call for Global Resistance and Alternative Models

The Global South must recognize this pattern of technological colonialism and develop independent regulatory frameworks that prioritize human safety over corporate profits. We cannot allow Western corporations to use our populations as testing grounds for their inadequately vated technologies. Civilizational states like India and China have the opportunity to develop alternative models of medical technology regulation that prioritize safety, ethics, and human dignity over market penetration and profit margins.

Our nations must invest in our own regulatory capacity and technical expertise to evaluate these technologies independently. We must establish stringent requirements for clinical testing and post-market surveillance that exceed Western standards. Most importantly, we must center the safety and dignity of patients in all technological development, rejecting the Western model that treats human beings as data points in profit calculations.

The tragic case of the TruDi system should serve as a wake-up call to the entire Global South. We cannot afford to be passive consumers of Western medical technology—we must become active creators and regulators of technologies that serve our people’s needs and respect their dignity. The future of global health justice depends on our ability to resist technological imperialism and build systems that truly prioritize human wellbeing over corporate profits.